Showing results (171-180 of 265) with videos related to

Sort By:
Pageof 27
Blood|November 24, 2001
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapyO Kirk, C Pedersen, A Cozzi-Lepri, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 4, 2001
Large de novo deletion in chromosome 12 affecting the PAH, IGF1, ASCL1, and TRA1 genesJ Mallolas, M A Vilaseca, C Pavia, et al.
Neuroscience|April 1, 2014
The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteinsS Camós, C Gubern, M Sobrado, et al.
Infection Control and Hospital Epidemiology|June 1, 1995
A cluster of fever and hypotension on a surgical intensive care unit related to the contamination of plasma expanders by cell wall products of Bacillus stearothermophilusA Trilla, C Codina, M Salles, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|July 29, 2010
[Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy]M T Martín, M Rovira, M Massanes, et al.
HIV Medicine|April 23, 2010
Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adultsR González, P Castro, F García, et al.
HIV Medicine|July 21, 2021
Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trialB Torres, A C Guardo, M Squarcia, et al.
AIDS (London, England)|March 1, 1994
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)J W Mulder, D A Cooper, L Mathiesen, et al.
Reviews of Infectious Diseases|March 1, 1989
Diagnostic value of serum antibody and antigen detection in heroin addicts with systemic candidiasisJ Bisbe, J M Miro, J M Torres, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2005
Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infectionM Arnedo-Valero, F Garcia, C Gil, et al.
Pageof 27